Ifeanyi Olele
Psychiatry · Fairfax, VANPI 1194132407
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 33.5% of the total. 2025 is the largest year on record at $68,467, more than ten times the $345 reported in 2019. Among psychiatry clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 473 payments — averaging $211.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$34K
- Axsome Therapeutics, Inc.$26K
- AbbVie$14K
- Ironshore Pharmaceuticals Inc.$7K
- Takeda Pharmaceuticals U.S.A., Inc.$7K
- Collegium Pharmaceutical, Inc.$6K
- plus $6K from 20 others
What the payments were for
- Consulting fees$31,96432%
- Speaking & faculty fees$50,58050%
- Travel & lodging$6,1976%
- Food & beverage$11,33311%
- Education$1650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 58 | $33,617 |
| Axsome Therapeutics, Inc. | 48 | $26,140 |
| AbbVie(2 entities) | 78 | $13,522 |
| Ironshore Pharmaceuticals Inc. | 34 | $7,373 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $6,946 |
| Collegium Pharmaceutical, Inc. | 30 | $6,223 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $1,675 |
| Otsuka America Pharmaceutical, Inc. | 40 | $652 |
| Sunovion Pharmaceuticals Inc. | 29 | $565 |
| Neuronetics, Inc. | 10 | $561 |
| Vanda Pharmaceuticals Inc. | 20 | $487 |
| Alkermes, Inc. | 18 | $442 |
| Supernus Pharmaceuticals, Inc. | 22 | $417 |
| Lundbeck LLC | 14 | $271 |
| Teva Pharmaceuticals USA, Inc. | 10 | $228 |
| Harmony Biosciences LLC | 5 | $210 |
| E.r. Squibb & Sons, L.L.C. | 4 | $208 |
| Bausch Health US, LLC | 10 | $200 |
| Neurocrine Biosciences, Inc. | 5 | $110 |
| Johnson & Johnson | 5 | $101 |
| Jazz Pharmaceuticals Inc. | 3 | $98 |
| Corium, LLC | 5 | $78 |
| Janssen Scientific Affairs, LLC | 1 | $51 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $25 |
| Tempus AI, Inc | 1 | $22 |
| Vertical Pharmaceuticals, LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$32,806
- Auvelity$25,133
- JORNAY PM$12,504
- VRAYLAR$12,335
- TRINTELLIX$6,624
- ARISTADA$478
- NEUROSTAR TMS THERAPY$181
- NEUROSTAR TMS THERAPY SYSTEM$170
- COBENFY$168
- Wakix$127
- ARISTADA INITIO$120
- Fanapt$111
How this compares
$100,240 in reported general payments places this provider in the 95th percentile of 884 psychiatry providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvanseLisdexamfetamine Dimesylate | 12 | $6,147 |
| Bupropion XlBupropion Hcl | 18 | $783 |
| Duloxetine Hcl | 19 | $655 |
| Buspirone Hcl | 23 | $612 |
| Quetiapine Fumarate | 40 | $598 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 11 | $571 |
| Temazepam | 11 | $534 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 19 | $449 |
| Lamotrigine | 27 | $439 |
| Clonazepam | 49 | $385 |
| Sertraline Hcl | 13 | $192 |
| Pregabalin | 13 | $183 |
| Zolpidem Tartrate | 16 | $128 |
| Trazodone Hcl | 16 | $116 |
| Alprazolam | 17 | $42 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $6,946 | $6,14712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 884 psychiatry providers in Virginia.
Other psychiatry in Fairfax
- David ClaytonFairfax$15K
- Maria TsaoFairfax$11K
- Alok KumarFairfax$9K
- Siddharth BajpaiFairfax$8K
- Niku SinghFalls Church$2.5M
- David ScheidererRoanoke$2.4M
- Kent McDanielGlen Allen$2.1M
- Jasdeep MiglaniManassas$958K
- David SpiegelNorfolk$565K
- William YetterVirginia Beach$312K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.